JNJ Extends Unbroken Dividend Run to 64 Years

Johnson & Johnson has maintained its impressive dividend streak for an unprecedented 64 years, reinforcing its reputation as one of the safest income investments in a volatile market. The healthcare giant's commitment to paying dividends is unwavering, with quarterly payouts rising from $1.30 to $1.34 per share - a 3.1% increase. This translates to an annualized dividend of around $5.36 per share, yielding approximately 2%. With a total shareholder yield higher due to stock buybacks, the company's payout ratio is a respectable 47%, leaving room for reinvestment and risk absorption.

The company operates through two main divisions: Innovative Medicine and MedTech. The former sells branded therapies across various disease areas, while the latter produces surgical tools, cardiovascular equipment, and contact lenses. Johnson & Johnson has diversified its revenue streams by having 28 platforms generate at least $1 billion in annual sales. This reduces reliance on any single product or market.

Recent quarterly sales rose almost 7% to approximately $25.31 billion, driven by oncology and immunology drugs such as Darzalex and Tremfya. The MedTech segment is undergoing a portfolio reshaping, exiting the DePuy Synthes orthopedics business to focus on faster-growing areas with higher margins. The company has filed for U.S. FDA approval of its Ottava robotic surgical system.